Criblage de modulateurs cycliques di-GMP à l’aide de bactéries exprimant une protéine rapporteure fluorescente

Executive Industry Relevance

This assay enables high-throughput screening of small molecules that modulate cyclic di-GMP signaling, a key virulence regulator in pathogenic bacteria. By linking c-di-GMP levels to GFP fluorescence, it provides a quantitative, reproducible readout for target de-risking in antimicrobial discovery. The approach supports early identification of compounds that attenuate bacterial pathogenicity without bactericidal pressure, reducing resistance development risk.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates the therapeutic hypothesis that c-di-GMP modulation attenuates virulence in Gram-negative pathogens.
• Operational Value: Uses a genetically encoded reporter to functionally validate c-di-GMP as a druggable target in Pseudomonas aeruginosa.
• Predictive Value: Enables mechanism-based triage of compounds that suppress intracellular signaling rather than growth.

Screening & Assay Development

• Assay Readiness: Prepares a standardized, fluorescence-based system for compound library screening in multi-well format.
• Quantitative Output: Measures GFP fluorescence at 485/520 nm to correlate compound treatment with c-di-GMP-dependent promoter activity.
• Reproducibility: Employs Z-prime analysis and negative controls to ensure assay uniformity across plates and runs.

Translational & Preclinical Research

• Disease Relevance: Targets c-di-GMP, a conserved regulator of biofilm formation and virulence in clinically relevant pathogens.
• Translational Continuity: Supports progression from hit identification to lead optimization by providing a mechanistic biomarker of target engagement.
• De-risking Value: Reduces false positives by distinguishing specific signaling inhibitors from general cytotoxic compounds via OD600 normalization.

Pipeline & Workflow Integration

The assay fits within the early discovery cascade, enabling primary screening of chemical libraries for anti-virulence hits before secondary validation in infection models.

• Discovery Biology: Tests target engagement by measuring fluorescence changes that reflect intracellular c-di-GMP dynamics.
• Screening: Delivers dose-response compatible, plate-based readouts suitable for automation and medium-throughput campaigns.
• Analytics: Generates percent inhibition data normalized to negative and positive controls for compound ranking.
• Translational Research: Connects in vitro target modulation to reduced virulence phenotypes, supporting go/no-go decisions for preclinical advancement.
• Enterprise Reuse: Establishes a plug-and-play platform adaptable to other c-di-GMP-regulated pathogens or promoter-reporter systems.

Operational & Enterprise Impact

• Scientific Value: Provides mechanistic confidence in target modulation, reducing ambiguity in phenotypic screening outcomes.
• Operational Value: Standardizes fluorescence measurement protocols, including gain, focus, and temperature controls for inter-lab reproducibility.
• Strategic Value: Enables prioritization of compounds with selective anti-virulence activity over broad growth inhibition.
• Portfolio Impact: Supports risk-adjusted investment in novel antimicrobial classes with lower resistance liability.

Implementation Considerations

• Requires expertise in bacterial genetics, plasmid transformation, and promoter-reporter validation.
• Dependent on plate reader capable of dual-wavelength OD600 and fluorescence detection with programmable gain/focus.
• Necessitates standardized compound preparation and DMSO tolerance testing to avoid false signals.
• Involves optimization of incubation time, temperature, and aeration for consistent bacterial growth and reporter expression.
• Limited to pathogens or models where c-di-GMP regulates a GFP-expressing promoter; not universally applicable without genetic modification.

Biopharma FAQs